Intravenous nalidixic acid in urogenital sepsis: report of 25 courses.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002701:Chloramphenicol / Q000627:therapeutic use; D003091:Colistin / Q000627:therapeutic use; D004755:Enterobacteriaceae / Q000187:drug effects; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009268:Nalidixic Acid / Q000008:administration & dosage / Q000097:blood / Q000627:therapeutic use*; D009582:Nitrofurantoin / Q000627:therapeutic use; D010403:Penicillin Resistance / Q000187:drug effects; D010406:Penicillins / Q000627:therapeutic use; D011113:Polymyxins / Q000627:therapeutic use; D018805:Sepsis / Q000188:drug therapy*; D014570:Urologic Diseases / Q000188:drug therapy*
D010406:Penicillins; D011113:Polymyxins; D009268:Nalidixic Acid; D007612:Kanamycin; D002701:Chloramphenicol; D009582:Nitrofurantoin; D003091:Colistin